Given that we observed focal loss of PTEN in normal human breast tissue, our findings indicate that a percentage of patients with stromal loss of PTEN might be at risk for subsequent breast cancer via epithelial EGFR/ErbB2 activation and subsequent genomic instability. The gene discussed is EGFR; the disease is breast cancer.